-
Min Investment
-
$244
-
Offering Date
-
December 16, 2022
-
Expected Close Date
-
February 15, 2023
-
Target Raise
-
$15.00K-$1.23M
-
No. Investors
-
8
-
Security Price
-
$7.40
-
Valuation
-
$49,950,000
- Number of Employees
- 3
- Cash
- $2,127
- Revenue
- $0
- Short Term Debt
- $296,233
- Cost of Goods
- $0
- Long Term Debt
- $609,996
- Net Income
- $-831,753
Company Description
CovInnovations™ is a life sciences company primarily focused on discovering and developing groundbreaking technologies that assess, diagnose, and treat COVID-19. With that, we have developed a potential cure for hospitalized patients with severe COVID-19 in need of oxygen supplementation - helping people bring back the immune response they need to fight the virus. Our company is in the R&D and prototyping stages and we intend to launch with this campaign. The Company is in the pre-revenue stage of development.
Key Deal Facts
We believe our clinical solution, COVI-001, has significant clinical efficacy, patent protection and a first-to-market position - satisfying clear unmet needs for COVID-19 patients and their healthcare providers.
There are more than 150K hospitalized patients with severe COVID-19 across the world daily (source). The Global COVID-19 Therapeutics Market is worth $14.6 Billion, and is expected to reach $25.6 Billion in 2030 (source).
Board and leadership team includes pharmaceutical executives with over 30 years of drug development, corporate and commercial leadership experience.
